Graft-Versus-Host Disease (Acute)

Comprehensive Clinical Guide: Acute Graft-Versus-Host Disease (aGVHD)

Acute Graft-Versus-Host Disease (aGVHD) remains the most significant immunological barrier to the success of allogeneic hematopoietic stem cell transplantation (HSCT). As a systemic disorder characterized by a multifaceted immune dysregulation, it represents a paradoxical scenario where the donor’s immune system recognizes the recipient’s tissues as foreign. This guide serves as a clinical reference for healthcare professionals, detailing the pathophysiology, staging, and therapeutic landscape of this complex diagnosis.

1. Introduction & Overview

Acute Graft-Versus-Host Disease (aGVHD) is a clinical syndrome occurring predominantly within the first 100 days post-transplantation, though "late-onset acute GVHD" can occur beyond this window. It occurs when immunocompetent donor T-cells, transplanted into a lymphopenic host, recognize and mount an inflammatory response against recipient human leukocyte antigens (HLA).

Epidemiological Context

Despite advancements in immunosuppressive prophylaxis (e.g., calcineurin inhibitors, methotrexate, post-transplant cyclophosphamide), aGVHD continues to affect 30–50% of patients receiving matched related donor transplants and upwards of 50–70% of those receiving matched unrelated donor transplants. The morbidity associated with aGVHD is significant, often leading to multi-organ failure and susceptibility to opportunistic infections.

2. Pathophysiology: The Three-Step Cascade

The pathogenesis of aGVHD is classically described as a three-phase biological cascade. Understanding these phases is critical for targeted therapeutic interventions.

Phase I: The Afferent Phase (Conditioning)

The conditioning regimen (chemotherapy/radiation) causes damage to host tissues, particularly the gastrointestinal tract. This damage leads to the release of damage-associated molecular patterns (DAMPs) and pro-inflammatory cytokines, including TNF-α, IL-1, and IL-6. This "cytokine storm" upregulates the expression of MHC molecules and adhesion molecules on host tissues, priming the environment for immune activation.

Phase II: The Activation Phase

Donor T-cells are activated upon encountering host antigen-presenting cells (APCs). The donor T-cells proliferate and differentiate into effector cells (Th1 and Th17 phenotypes). These cells migrate to target organs, guided by chemokine gradients.

Phase III: The Effector Phase

The final phase involves the actual tissue destruction. Cytotoxic T-lymphocytes (CTLs) and Natural Killer (NK) cells infiltrate target organs, releasing granzymes, perforins, and further pro-inflammatory cytokines, leading to apoptosis of epithelial cells in the skin, liver, and GI tract.

3. Clinical Staging and Grading

Standardization of aGVHD assessment is vital for clinical trials and prognostic stratification. The Modified Glucksberg Criteria and the Mount Sinai Acute GVHD International Consortium (MAGIC) criteria are the current gold standards.

Table 1: Organ-Specific Staging

Overall Clinical Grading

• Grade I: Skin Stage 1–2, no liver/GI involvement.
• Grade II: Skin Stage 3 OR Liver/GI Stage 1.
• Grade III: Liver/GI Stage 2–3 OR Skin Stage 4.
• Grade IV: Severe organ dysfunction (Stage 4 in any organ).

4. Standard Presentation and Differential Diagnosis

Clinical Presentation

The hallmark symptoms include:
1. Dermatological: Maculopapular rash, typically starting on the palms, soles, and ears before spreading to the trunk.
2. Gastrointestinal: Secretory diarrhea, abdominal cramping, nausea, and vomiting.
3. Hepatobiliary: Cholestatic jaundice, characterized by elevated bilirubin and alkaline phosphatase with minimal transaminase elevation.

Differential Diagnosis

It is imperative to rule out non-GVHD etiologies before initiating high-dose systemic steroids:
* Drug Eruptions: Common post-transplant due to antibiotic/antifungal usage.
* Viral Infections: CMV, EBV, or Adenovirus enteritis.
* Veno-Occlusive Disease (VOD/SOS): Liver involvement mimicking GVHD.
* Conditioning Toxicity: Mucositis and drug-induced hepatotoxicity.

5. Diagnostic Investigations

Diagnosis is primarily clinical, but histological confirmation is the gold standard.

• Skin Biopsy: Punch biopsy is the most common diagnostic procedure. Histology shows basal vacuolar degeneration and lymphocytic infiltration at the dermo-epidermal junction.
• Endoscopy/Colonoscopy: Essential for GI-aGVHD. Biopsies reveal crypt cell apoptosis (crypt abscesses).
• Biomarkers: The MAGIC algorithm (using ST2 and REG3α plasma levels) is increasingly used to predict non-relapse mortality and treatment response.

6. Management and Therapeutic Approaches

First-Line Therapy

Systemic corticosteroids (Methylprednisolone 1–2 mg/kg/day) remain the cornerstone of treatment. Patients who respond are typically tapered slowly over several weeks to months.

Steroid-Refractory aGVHD (SR-aGVHD)

Patients failing to respond to steroids within 3–5 days are classified as SR-aGVHD. Second-line agents include:
* Ruxolitinib: A JAK1/2 inhibitor, currently FDA-approved for SR-aGVHD.
* Extracorporeal Photopheresis (ECP): An immunomodulatory procedure.
* Mesenchymal Stromal Cells (MSCs): Investigational, showing promise in modulating T-cell responses.
* Vedolizumab: An anti-integrin antibody targeting gut-specific inflammation.

7. Prognosis and Long-Term Considerations

The prognosis for aGVHD is highly dependent on the grade and the response to initial steroid therapy.
* Grade I-II: Generally carry a favorable prognosis with appropriate management.
* Grade III-IV: Associated with high non-relapse mortality (NRM), often exceeding 50% due to complications like sepsis or profound immunosuppression.

Long-term sequelae include chronic GVHD, which may occur in patients who recover from acute disease, leading to fibrosis, scleroderma-like changes, and permanent organ dysfunction.

8. Frequently Asked Questions (FAQ)

1. Is aGVHD the same as transplant rejection?

No. Transplant rejection involves the recipient's immune system attacking the donor's graft. aGVHD is the exact opposite: the donor's immune cells attack the recipient's body.

2. Can aGVHD be prevented?

Yes, prophylaxis is standard. It typically involves calcineurin inhibitors (Tacrolimus/Cyclosporine) combined with Methotrexate or Mycophenolate Mofetil. Post-transplant cyclophosphamide is also widely used in haploidentical transplants.

3. Does aGVHD mean the transplant failed?

Not necessarily. A mild "Graft-versus-Leukemia" (GVL) effect is often desired, as the same T-cells attacking the host tissues may also destroy residual malignant cells.

4. How quickly does aGVHD develop?

Classically within 100 days of the infusion of hematopoietic stem cells.

5. What is the role of biopsy?

Biopsy confirms the diagnosis and excludes mimics like CMV colitis or drug toxicity, which require drastically different treatments.

6. What is "Steroid-Refractory" GVHD?

It is defined as progression of symptoms after 3–5 days of 2 mg/kg/day of methylprednisolone or failure to achieve improvement after 7 days.

7. Are there long-term skin issues?

Yes, severe acute skin GVHD can lead to post-inflammatory hyperpigmentation or, if it transitions to chronic GVHD, skin tightening and atrophy.

8. Can aGVHD affect the eyes?

Yes, it can manifest as severe keratoconjunctivitis sicca (dry eyes), which is more commonly associated with chronic GVHD but can present early.

9. How do we monitor for liver aGVHD?

Monitoring is done via serial liver function tests (LFTs). A disproportionate rise in bilirubin compared to transaminases is a classic indicator of hepatic GVHD.

10. Does age affect the risk of aGVHD?

Yes, older patients generally have a higher incidence and severity of aGVHD, likely due to immunosenescence and higher cumulative comorbidities.

9. Conclusion

Acute Graft-Versus-Host Disease remains a critical challenge in clinical hematology. Success in managing this disease relies on a high index of clinical suspicion, rapid diagnostic confirmation, and the judicious use of immunosuppressive agents. As we move toward more personalized medicine, the integration of plasma biomarker panels and targeted small-molecule inhibitors like Ruxolitinib is shifting the paradigm from broad immunosuppression to precise immune modulation, ultimately aiming to improve survival in the post-transplant population.

Disclaimer: This guide is intended for medical professionals and educational purposes only. It does not replace institutional protocols or the clinical judgment of the attending hematologist/oncologist.

Related Clinical Integration

In the management of acute Graft-Versus-Host Disease (aGVHD), the primary clinical objective is the rapid suppression of donor T-cell activity to mitigate systemic inflammatory damage. First-line therapy typically involves high-dose corticosteroids, such as Prednisone / بريدنيزون 5 mg, to modulate the immune response. For patients who are refractory to steroids or require steroid-sparing strategies, calcineurin inhibitors remain the cornerstone of treatment, necessitating the administration of Cyclosporine / سيكلوسبورين 100mg or Tacrolimus / تاكروليموس 1mg to maintain therapeutic immunosuppression. In cases of severe, steroid-resistant aGVHD, clinicians may escalate care by incorporating targeted biological agents, such as Infliximab / إنفليكسيماب 100mg, to neutralize pro-inflammatory cytokines and improve clinical outcomes within the hospital setting.